BioLight Life Sciences Ltd. (IL:BOLT)
TASE:BOLT
Want to see IL:BOLT full AI Analyst Report?
Top Page
Biolight
(TASE:BOLT)
Select Model
Select Model
Rating:45Neutral
Price Target:
269.00
▼(-27.57% Downside)
Action:Reiterated
Date:05/20/26
The score is primarily held back by weak financial performance—zero/volatile revenue, sustained losses, and persistent cash burn—despite low leverage. Technicals are mixed with modest near-term strength but negative longer-term trend signals, while valuation offers limited support due to negative earnings and no dividend yield data.
Positive Factors
Low Leverage
Very low debt-to-equity materially reduces refinancing and solvency risk versus leveraged peers. This durable balance-sheet characteristic provides structural financial flexibility to support multi-quarter R&D programs and reduces near-term default risk even with weak cash generation.
Negative Factors
Revenue Collapse
Revenue falling to zero in 2025 indicates an absence of recurring commercial sales and no near-term internal cash generation. Over the coming months this lack of revenue removes a sustainable funding source, increasing dependence on external capital and weakening the firm's operational resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low debt-to-equity materially reduces refinancing and solvency risk versus leveraged peers. This durable balance-sheet characteristic provides structural financial flexibility to support multi-quarter R&D programs and reduces near-term default risk even with weak cash generation.
Read all positive factors
Biolight (BOLT) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪26.59M
Dividend YieldN/A
Average Volume (3M)11.86K
Price to Earnings (P/E)―
Beta (1Y)0.70
Revenue Growth-100.00%
EPS Growth-29.02%
CountryIL
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.98
Shares Outstanding9,079,270
10 Day Avg. Volume7,448
30 Day Avg. Volume11,863
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biolight Business Overview & Revenue Model
Company Description
BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline incl...
How the Company Makes Money
null...
Biolight Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 219.00K | 118.00K | 63.00K | 3.00K |
| Gross Profit | -544.00K | 219.00K | 118.00K | 63.00K | 3.00K |
| EBITDA | -14.66M | -7.75M | -10.60M | -8.03M | -1.31M |
| Net Income | -11.73M | -7.14M | -26.02M | -7.85M | 382.00K |
Balance Sheet | |||||
| Total Assets | 42.41M | 34.12M | 33.45M | 57.01M | 64.17M |
| Cash, Cash Equivalents and Short-Term Investments | 23.65M | 13.47M | 8.64M | 17.63M | 33.71M |
| Total Debt | 772.00K | 599.00K | 91.00K | 527.00K | 443.00K |
| Total Liabilities | 2.24M | 3.38M | 3.15M | 3.32M | 2.75M |
| Stockholders Equity | 34.40M | 26.88M | 29.78M | 53.17M | 60.70M |
Cash Flow | |||||
| Free Cash Flow | -10.86M | -11.02M | -10.99M | -9.64M | -10.65M |
| Operating Cash Flow | -10.85M | -10.99M | -9.58M | -9.54M | -10.03M |
| Investing Cash Flow | -16.17M | 7.55M | -1.95M | -10.55M | 13.48M |
| Financing Cash Flow | 21.37M | 7.98M | 3.25M | -485.00K | 915.00K |
Biolight Technical Analysis
Negative
371.40
Price Trends
275.51
Positive
311.53
Negative
364.90
Negative
Market Momentum
1.46
Positive
50.15
Neutral
36.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BOLT, the sentiment is Negative. The current price of 371.4 is above the 20-day moving average (MA) of 304.02, above the 50-day MA of 275.51, and above the 200-day MA of 364.90, indicating a neutral trend. The MACD of 1.46 indicates Positive momentum. The RSI at 50.15 is Neutral, neither overbought nor oversold. The STOCH value of 36.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BOLT.
Biolight Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₪41.94M | -1.63 | ― | ― | -94.40% | 31.61% | |
46 Neutral | ₪18.18M | -725.22 | ― | ― | ― | ― | |
45 Neutral | ₪26.59M | -2.09 | ― | ― | -100.00% | -29.02% | |
43 Neutral | ₪20.26M | -0.24 | ― | ― | ― | -17.14% |
* Healthcare Sector Average
IL:BOLT
Biolight
292.90
-246.00
-45.65%
IL:XTLB
Xtl Bio
1.70
-2.40
-58.54%
IL:BLRX
Bioline Rx
1.60
-1.30
-44.83%
IL:CANF
Can Fite Bio
424.30
423.00
32538.46%
IL:PPBT
Purple Biotech
1.00
-3.30
-76.74%
IL:MTLF
Matricelf
282.80
13.40
4.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.